# US 2004/0071671 A1 · Cell therapy method for the treatment of tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0071671 A1
- Document ID: US20040071671A1
- Status: Published application
- Kind: A1
- Application number: 10/289,566
- Filed: 2002-11-07
- Published: 2004-04-15
- Earliest claimed: 2001-02-20
- Inventors: Didier J. Leturcq; Ann M. Moriarty; Michael R. Jackson; Per A. Peterson; Jon M. Richard
- Web page: https://patentgrep.com/patent/US20040071671A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 38/2013: {IL-2}
- A61K 38/212: {IFN-alpha}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/35: Cytokines
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4214: {Receptors for cytokines}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 40/4235: {Interferons [IFN]}
- A61K 40/4244: {Enzymes}
- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61K 40/4266: {Carcinoembryonic antigen [CEA]}
- A61K 40/4268: {MAGE}
- A61K 40/4269: {NY-ESO}
- A61K 40/4271: {Melanoma antigens}
- A61K 40/4272: {Melan-A/MART}
- A61K 40/4273: {Glycoprotein 100 [Gp100]}
- A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- C12N 5/0601: {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/55527: {Interleukins}
- A61K 2039/55533: {IL-2}
- A61K 2039/55538: {IL-12}
- A61K 2239/49: Breast
- C12N 2501/23: Interleukins [IL]
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/99: genetically modified cells
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCS; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.

## Claims

### Claim 1

A method for treating a viral infection in a subject comprising:
a. preparing a non-naturally occurring antigen-presenting cell line(nnAPC), wherein said nnAPC is capable of presenting up to about fifteen different peptide molecules associated with said viral infection simultaneously wherein said peptide molecules are each about six to twelve amino acids in length,
b. harvesting CD8+ cells from said subject or a suitable donor;
c. stimulating said CD8+ cells with said nnAPC cell line;
d. adding said CD8+ cells to media that contains a cytokine selected from the group consisting of IL-2, IL-7 or conditioned growth medium (CGM), wherein said cytokines can be used individually or in combination;
e. mixing unsuspended peripheral blood monocytes, or CD-8 depleted peripheral blood monocytes collected from said subject or a suitable donor with about 1 to 50 μg/ml of one of said peptides that said nnAPC can simultaneously present;
f. irradiating said peripheral blood monocyte suspension with a sufficient dose of γ-radiation necessary to sterilize all components in the suspension, except the desired peripheral blood monocytes;
g. isolating adherent peripheral blood monocytes;
h. loading said adherent peripheral blood monocytes with about 1 ug/ml to 50 μg/ml of said each peptide;
i. combining said CD8+ cells with said adherent peripheral blood monocytes at a ratio of about ten CD8+ cells to one peripheral blood monocyte; and
j. inoculating said subject with the CD8+ suspension.

### Claim 2 (depends on 1)

The method of claim 1 wherein said nnAPC is capable of presenting up to about ten peptide molecules.

### Claim 3 (depends on 1)

The method of claim 1 wherein said peptide molecules are about eight to ten amino acids in length

### Claim 4 (depends on 1)

The method of claim 1 wherein said peptide molecules are in a concentration range of about 10 nM to 100 μM.

### Claim 5 (depends on 1)

The method of claim 1 wherein said cytokine component is IL-2.

### Claim 6 (depends on 1)

The method of claim 1 wherein said cytokine component is IL-2 and IL-7 in combination

### Claim 7 (depends on 1)

The method of claim 1 wherein the dose of γ-radiation is about 3,000 to 7,000 rads.

### Claim 8 (depends on 1)

The method of claim 1 wherein the dose of γ-radiation is about 5,000 rads.

### Claim 9

A method for treating a subject with melanoma, comprising the steps of:
a. administering to said subject an effective amount of interferon-alfa that is capable of enhancing the expression of tumor antigen on the surface of the tumor; and
b. inoculating said subject with an effective amount of autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen.

### Claim 10 (depends on 9)

The method of claim 9, further comprising the step of administering to said subject an effective amount of interleukin-2 that is capable of enhancing the in vivo maintenance of the autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen.

### Claim 11 (depends on 10)

The method of claim 10, wherein the interferon-alfa is selected from interferon-alfa-2a or interferon-alfa-2b.

### Claim 12 (depends on 10)

The method of claim 10, wherein the effective amount of interferon-alfa is about 10 MU/m2/day and is subcutaneously administered to the subject consecutively from day 5 to day 1 prior to inoculating said subject with the effective amount of autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen.

### Claim 13 (depends on 10)

The method of claim 10, wherein the effective amount of autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen is about 1-10×109 cells/infusion.

### Claim 14 (depends on 10)

The method of claim 10, wherein the autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen are obtained by a method comprising steps of:
a) preparing a non-naturally occurring antigen-presenting cell line (nnAPC), wherein said nnAPC is capable of presenting up to about fifteen different epitopes associated with said melanoma simultaneously and where each epitope is a peptide of eight to ten amino acids in length;
b) loading the nnAPC with up to about fifteen different epitopes associated with said melanoma;
c) harvesting CD8+ cells from said subject;
d) stimulating said CD8+ cells with the epitope-loaded nnAPC cell line to obtain CD8+ cells specific for the melanoma;
e) growing the CD8+ cells specific for the melanoma in media containing IL-2 and IL-7;
f) mixing CD8-depleted peripheral blood monocytes collected from said subject with each epitope used for nnAPC loading;
g) irradiating said CD8-depleted peripheral blood monocytes with γ-radiation;
h) isolating adherent CD8-depleted peripheral blood monocytes;
i) loading said adherent peripheral blood monocytes with each epitope used for nnAPC loading;
j) restimulating said CD8+ cells specific for the melanoma with the epitope-loaded adherent peripheral blood monocytes;
k) growing the restimulated CD8+ cells specific for the melanoma in media containing IL-2 and IL-7; and
l) expanding the restimulated CD8+ cells specific for the melanoma by OKT3 antibody stimulation.

### Claim 15 (depends on 14)

The method of claim 14, wherein step 0) can be repeated at least one more time.

### Claim 16 (depends on 14)

The method of claim 14, wherein said non-naturally occurring antigen-presenting cell line is loaded with epitopes that are peptides derived from tyrosinase, gp100, and MART-1.

### Claim 17 (depends on 16)

The method of claim 16, wherein said non-naturally occurring antigen-presenting cell line is loaded with epitopes comprising amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

### Claim 18 (depends on 14)

The method of claim 14, wherein the effective amount of interleukin-2 is about 3 MIU/day and is subcutaneously administered to the subject consecutively from day 0 to day 28 after inoculating said subject with the effective amount of autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen.

### Claim 19 (depends on 14)

The method of claim 14, wherein the method is repeated at an interval of about 2 months.

### Claim 20 (depends on 19)

The method of claim 19, wherein the method is repeated for at least two cycles and further comprises the step of evaluating a response in said subject after each cycle.

### Claim 21 (depends on 14)

The method of claim 14, comprising the steps of:
a. subcutaneously administering to the subject 10 MU/m2/day of interferon-alpha-2b consecutively from day 5 to day 1 prior to inoculating said subject with autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen;
b. introducing about 1-10×109 cells/infusion of the autologous cytotoxic T lymphocytes with specificity for melanoma-associated target antigen to the subject; and
c. subcutaneously administering to the subject about 3 MIU/day of interleukin-2 consecutively from day 0 to day 28 following the introducing step.
